**AR-23 derivatives with high endosomal disrupting ability enhance Poly(L-lysine)-mediated gene transfection**

Shi-Kun Zhang1#, Lin Gong1,3#, Xue Zhang1, Zhi-min Yun1, Su-Bo Li1, Hong-Wei Gao1, Cong-Jie Dai2，Jian-Jun Yuan2，Jing-ming Chen4, Feng Gong\*1, Ying-Xia Tan\*1, Shou-Ping Ji\*1,2


1. Department of Stem Cell and Regenerative Medicine, Institute of Health Service and Transfusion Medicine, Beijing, China.
2. College of Oceanology and Food Sciences，Quanzhou Normal University, Quanzhou, Fujian.
3. PLA navy No. 971hospital, Qingdao, Shandong.
4. Quanzhou Preschool Education College, Quanzhou, Fujian.

\*Correspondence to: Shou-Ping Ji, Ying-Xia Tan and Feng Gong. Department of Stem Cell and Regenerative Medicine Laboratory, Institute of Health Service and Transfusion Medicine, 27 Taiping Road, Beijing 100850, China. Tel.: +8601066931937; fax: +8601068151876 E-mail: jisp2020@qztc.edu.cn; tuanhu333@126.com; gongfeng@nic.bmi.ac.cn.

# these authors contributed equally to this work.



**Figure s1.** Agarose gel electrophoresis of PLL/DNA and PEI/DNA/peptide; the peptide was added at different concentrations as indicated behind the peptide. 1. Marker; 2. DNA (Plasmid); 3. PLL/DNA; 4. PLL/DNA + AR-23 (2.5 µM); 5. PLL/DNA + aAR1 (10 µM); 6. PLL/DNA + aAR2 (20 µM); 7. PLL/DNA + aAR3 (40 µM).



**Figure s2.** Transfection efficiency of PLL/DNA and PLL/DNA/peptide in HEK-293 cells, images were acquired with an inverted fluorescence microscope (scale bar = 50 µm). A. PLL/DNA; B. PLL/DNA + AR-23 (2.5 µM); C. PLL/DNA + aAR3 (5 µM); D PLL/DNA + aAR2 (20 µM); E. PLL/DNA + aAR3 (40 µM); F. Lipfectamine 2000.